50 completed, 20 unknown, 8 terminated, 6 recruiting. 94 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 94 | Completed 50, Unknown 20, Terminated 8, Recruiting 6, Withdrawn 4, Enrolling by invitation 2, Not yet recruiting 2, Active not recruiting 1, Suspended 1 |
Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease Finerenone (BAY 94-8862), Placebo - Albuminuria, Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 148 | 2026-07-01 | 2026-06-25 |
| Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease Dapagliflozin (10mg Tab), Placebo - Chronic Kidney Disease (Mild to Moderate), Albuminuria | Phase 4 | Recruiting | Centenario Hospital Miguel Hidalgo | 200 | 2026-04-23 | 2026-04-27 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients Huaier Granule, Anlotinib and Bevacizumab - Proteinuria | Phase 4 | Not yet recruiting | Fudan University | 40 | 2026-01-28 | 2026-01-22 |
| Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA) - Type 2 DM, Type 2 DM /Diabetic Nephropathy | Phase 4 | Enrolling by invitation | Steno Diabetes Center Copenhagen | 50 | 2025-11-20 | 2025-12-22 |
| Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis Sparsentan - Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Active not recruiting | Travere Therapeutics, Inc. | 20 | 2025-10-07 | 2026-06-23 |
| Nefecon and Ambrisentan in IgA Nephropathy "Nefecon®","Ambrisentan" - IgA Nephropathy, Chronic Kidney Disease | Phase 4 | Recruiting | The First Hospital of Jilin University | 129 | 2025-09-01 | 2025-09-15 |
| Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Empagliflozin 10 MG, Finerenone, Withings BPM Connect - Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2 | Phase 4 | Completed | University Medical Center Groningen | 12 | 2024-07-29 | 2026-02-13 |
| Empagliflozin Treatment in Kidney Transplant Recipients Empagliflozin - Kidney Transplant, Chronic Kidney Disease | Phase 4 | Recruiting | VA Office of Research and Development | 264 | 2024-04-05 | 2026-04-21 |
| Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT) Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination - Alport Syndrome, Thin Basement Membrane Disease | Phase 4 | Completed | Stefan Lujinschi | 12 | 2024-02-26 | 2026-06-25 |
| Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome. Dapagliflozin and Standard therapy (ACEI or ARB)., Standard Therapy (ACEI or ARB). - Nephrotic Syndrome | Phase 4 | Unknown | Ain Shams University | 90 | 2023-08-01 | 2023-08-01 |
| Role of Vitamin K2 in Chronic Kidney Disease Placebo, Vitamin K 2 - Chronic Kidney Diseases | Phase 4 | Recruiting | Tanta University | 44 | 2023-07-15 | 2025-06-24 |
| Role of Coenzyme Q10 in Chronic Kidney Disease Placebo, Co-Enzyme Q10 - Chronic Kidney Diseases | Phase 4 | Recruiting | Tanta University | 44 | 2023-07-15 | 2025-06-19 |
| Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes Montelukast, Placebo - Albuminuria | Phase 4 | Recruiting | University of Colorado, Denver | 50 | 2023-01-26 | 2026-06-30 |
| Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Dapagliflozin 10mg Tab, Placebo, Withings BPM Connect - Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria | Phase 4 | Completed | University Medical Center Groningen | 20 | 2021-05-11 | 2024-04-22 |
| Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease ACEI treatment, Dapagliflozin+ACEI treatment - Proteinuria, Chronic Kidney Diseases | Phase 4 | Withdrawn | Children's Hospital of Fudan University | 2021-01-01 | 2020-12-29 | |
| Intravenous Administration of Vitamin B Complex Improves Renal Recovery in Patients With AKI Vitamin B Complex, STOP AKI protocol - Acute Kidney Injury | Phase 4 | Completed | Caja Nacional de Salud | 260 | 2020-09-01 | 2025-01-30 |
| Efficacy and Safety of Dapagliflozin in Children With Proteinuria Dapagliflozin - Proteinuria | Phase 4 | Completed | Children's Hospital of Fudan University | 23 | 2020-07-06 | 2022-06-21 |
| Rituximab and RASi in Patients with IgAN Rituximab, RAS 2410 - IgA Nephropathy | Phase 4 | Completed | Nan Chen,MD | 116 | 2020-07-01 | 2025-03-14 |
| Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes SGLT2 Inhibition - Type 2 Diabetes, Diabetic Nephropathy | Phase 4 | Unknown | Zhongshan Hospital Xiamen University | 70 | 2019-10-15 | 2019-10-21 |
Showing 20 of 94. Sign in to see all of them.
Albuminuria (30) · Renal Insufficiency, Chronic (28) · Diabetes Mellitus, Type 2 (17) · Hypertension (17) · Diabetes Mellitus (13) · Glomerulonephritis, IGA (13) · Diabetic Nephropathies (12) · Kidney Diseases (5) · Glomerulonephritis (4) · Glomerulonephritis, Membranous (4) · Kidney Failure, Chronic (4) · Nephrotic Syndrome (4) · Glomerulosclerosis, Focal Segmental (3) · Lupus Nephritis (3)
Female Urogenital Diseases (94) · Female Urogenital Diseases and Pregnancy Complications (94) · Male Urogenital Diseases (94) · Pathological Conditions, Signs and Symptoms (94) · Signs and Symptoms (94) · Urination Disorders (94) · Urogenital Diseases (94) · Urologic Diseases (94) · Urological Manifestations (94) · Kidney Diseases (60) · Pathologic Processes (35) · Endocrine System Diseases (34) · Chronic Disease (32) · Disease Attributes (32) · Renal Insufficiency (32)
Valsartan (10) · aliskiren (9) · dapagliflozin (7) · Losartan (6) · Ramipril (6) · Amlodipine (4) · Angiotensin-Converting Enzyme Inhibitors (4) · Calcitriol (4) · benazepril (4) · finerenone (4) · Adrenocorticotropic Hormone (3) · Lisinopril (3) · Telmisartan (3) · empagliflozin (3) · trandolapril (3)
Novartis (6) · Gulhane School of Medicine (4) · The University of Hong Kong (3) · Abbott (2) · Children's Hospital of Fudan University (2) · Chinese PLA General Hospital (2) · Chinese University of Hong Kong (2) · Medical University of Gdansk (2) · Peter Rossing (2) · Shiga University (2) · Tanta University (2) · The Rogosin Institute (2) · University Medical Center Groningen (2) · A. Manzoni Hospital (1) · Ain Shams University (1)
United States (19) · China (17) · South Korea (7) · Canada (5) · Denmark (5) · Mexico (5) · Netherlands (5) · Spain (5) · Turkey (Türkiye) (5) · Australia (4) · Egypt (4) · France (4) · Italy (4) · Japan (4) · Switzerland (4)
Cheuk-Chun Szeto, MD (2) · Choli Hartono, MD (2) · Sydney CW Tang, MD (2) · Xiangmei Chen, MD.& Ph.D (2) · Andrea E Satta, MD (1) · Anne-Lise Kamper, DMSc (1) · Antonello Pani, MD (1) · Atsunori Kashiwagi, Professor (1) · Bertram Kasiske, M.D. (1) · Bum Soon Choi, PhD (1) · Chun-Soo Lim, PhD (1) · Claudio Ponticelli, MD (1) · Claudio Pozzi, MD (1)
PMID 38682786, PMID 26032537, PMID 33107592, PMID 34778952, PMID 38299639, PMID 16014059, PMID 17667984, PMID 18436082, PMID 18443191, PMID 18716365, PMID 19211665, PMID 19809363, PMID 20430947, PMID 20966122, PMID 21243736, PMID 21626222, PMID 21680850, PMID 22073219, PMID 22722778, PMID 22773704, PMID 22784975, PMID 22981148, PMID 23013602, PMID 23733198, PMID 23929932, PMID 23965522, PMID 24009220, PMID 24457184, PMID 24641955, PMID 25480673, PMID 25531146, PMID 25887073, PMID 26098847, PMID 26300986, PMID 26390102, PMID 27821627, PMID 28341782, PMID 28395659, PMID 28605608, PMID 28755807, PMID 29133604, PMID 29526832, PMID 29615792, PMID 29693360, PMID 29937267, PMID 29941478, PMID 29988921, PMID 30125457, PMID 30591006, PMID 30635226
2015 (1), R01DK060706 (1)